1. Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B
- Author
-
András Kotschy, Allan E. Surgenor, Andrea Fiumana, James Brooke Murray, Andrew Massey, Thomas Edmonds, Nicolas Foloppe, Didier Demarles, Pawel Dokurno, Mike Burbridge, Francisco Cruzalegui, K Benwell, Roderick E. Hubbard, Stuart C. Ray, Walmsley David, and Julia Smith
- Subjects
Models, Molecular ,DYRK1B ,DYRK1A ,Cellular differentiation ,Mice, Nude ,Antineoplastic Agents ,Mice, SCID ,Protein Serine-Threonine Kinases ,01 natural sciences ,Metastasis ,Serine ,Mice ,Structure-Activity Relationship ,03 medical and health sciences ,In vivo ,Cell Line, Tumor ,Drug Discovery ,medicine ,Animals ,Humans ,Protein Kinase Inhibitors ,Cell Proliferation ,030304 developmental biology ,Mice, Inbred BALB C ,0303 health sciences ,Dose-Response Relationship, Drug ,Molecular Structure ,Brain Neoplasms ,Kinase ,Chemistry ,Neoplasms, Experimental ,Protein-Tyrosine Kinases ,medicine.disease ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,Apoptosis ,Cancer research ,Molecular Medicine ,Female ,Drug Screening Assays, Antitumor - Abstract
The serine/threonine kinase DYRK1A has been implicated in regulation of a variety of cellular processes associated with cancer progression, including cell cycle control, DNA damage repair, protection from apoptosis, cell differentiation, and metastasis. In addition, elevated-level DYRK1A activity has been associated with increased severity of symptoms in Down's syndrome. A selective inhibitor of DYRK1A could therefore be of therapeutic benefit. We have used fragment and structure-based discovery methods to identify a highly selective, well-tolerated, brain-penetrant DYRK1A inhibitor which showed in vivo activity in a tumor model. The inhibitor provides a useful tool compound for further exploration of the effect of DYRK1A inhibition in models of disease.
- Published
- 2021